Joshua Ross, MD
Interventional Pain Medicine · Latham, NYNPI 1235557521
Payments from drug & device makers
What this record shows
15 manufacturers reported payments, led by Abbott at 35.7% of the total. Reporting peaked in 2019 at $2,251 and has fallen 95.2% since, to $109 in 2025.
Across 69 payments — averaging $71.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Nevro Corp.$1K
- Stryker$1K
- Boston Scientific$277
- Medtronic$47
- Ferring Pharmaceuticals Inc.$32
- plus $175 from 9 others
What the payments were for
- Travel & lodging$2,50451%
- Food & beverage$2,41549%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 21 | $1,755 |
| Nevro Corp. | 19 | $1,353 |
| Stryker | 9 | $1,279 |
| Boston Scientific | 6 | $277 |
| Medtronic(2 entities) | 3 | $47 |
| Ferring Pharmaceuticals Inc. | 2 | $32 |
| Foundation Fusion Solutions, LLC | 1 | $28 |
| Saluda Medical Americas, Inc. | 1 | $24 |
| Novartis | 1 | $23 |
| Relievant Medsystems, Inc. | 1 | $21 |
| Sirtex Medical Inc | 1 | $18 |
| Siemens Medical Solutions USA, Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Bard Peripheral Vascular, Inc. | 1 | $15 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Proclaim Family of SCS IPGs$1,265
- OPTABLATE$1,057
- SPINEJACK$1,057
- Senza Spinal Cord Stimulation System$526
- Omnia$515
- GENERAL PAIN MANAGEMENT$100
How this compares
$4,919 in reported general payments places this provider in the 60th percentile of 132 interventional pain medicine providers in New York.
See all interventional pain medicine providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Duloxetine Hcl | 236 | $8,067 |
| Pregabalin | 111 | $7,123 |
| Gabapentin | 256 | $2,721 |
| Methocarbamol | 121 | $1,640 |
| Tizanidine Hcl | 28 | $532 |
| Topiramate | 61 | $527 |
| Celecoxib | 20 | $438 |
| Diclofenac Sodium | 33 | $324 |
| Meloxicam | 78 | $315 |
| Cyclobenzaprine Hcl | 25 | $251 |
| Nortriptyline Hcl | 11 | $129 |
| Amitriptyline Hcl | 12 | $94 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Latham
- Corey HunterNew York$446K
- Neel MehtaNew York$432K
- Hemant KaliaRochester$179K
- Martin FerrilloAlbany$164K
- George ChaseKew Gardens$102K
- Kimberly SackheimNew York$102K
- Suelane OuroNew York$68K
- Gerard DegregorisNew York$49K
- Jafar SiddiquiWilliamsville$45K
- Alexander WeingartenSyosset$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.